

Cancer centers of excellence for the multidisciplinary management of urologic cancers: The intersection between education, research, and healthcareDaniel Andrés Nieva-Posso¹, Philippe E. Spiess^{2,3,4}, Herney Andrés García-Perdomo^{1,5}¹UROGIV Group Research, School of Medicine, Universidad del Valle, Cali, Colombia; ²Department of Genito-Urinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States;³Department of GU Oncology and Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States; ⁴Urology and Oncology, University of South Florida, Tampa, FL, United States;⁵Division of Urology/Uro-oncology, Department of Surgery, School of Medicine, Universidad del Valle. Cali, Colombia

Cite as: Nieva-Posso DA, Spiess PE, García-Perdomo HA. Cancer centers of excellence for the multidisciplinary management of urologic cancers: The intersection between education, research, and healthcare. *Can Urol Assoc J* 2024 March 1; Epub ahead of print. <http://dx.doi.org/10.5489/cuaj.8655>

Published online March 1, 2024

Corresponding author: Dr. Herney Andrés García-Perdomo Universidad del Valle, Cali, Colombia; herney.garcia@correounivalle.edu.co

ABSTRACT

Urologic cancers are among the leading causes of morbidity and mortality in the world, representing more than 10% of the total number of new cancer cases worldwide. These complex diseases are linked to several issues related to their diagnosis, management, monitoring, and treatment — issues that require multidisciplinary solutions that encompass and manage patients as complex entities. In response to this, the so-called cancer centers of excellence (CCEs) emerged, defined as multidisciplinary institutions specialized in the diagnosis, management, monitoring, and treatment of specific diseases, including cancer. Different institutions, such as the European Association of Urology (EAU), have proposed and encouraged its consolidation, especially for the management of prostate cancer. These institutions must be composed of three areas: healthcare, education, and research, which have complementary interactions and relationships, stimulating research and problem-solving from a multidisciplinary approach and also covering elements of basic sciences and mental health. The implementation of these CCEs has brought positive results; therefore, it is necessary to stimulate their implementation with a uro-oncologic approach.

INTRODUCTION

Cancer is a chronic, non-communicable disease characterized by uncontrolled cell proliferation and the lack of an efficient immune response [1]. It is a multifactorial disease, physically and emotionally impacting patients, family members, and/or caregivers [2]. Urological cancers involve organs of the genitourinary system, such as the bladder, prostate, kidney, testicles, penis, and urethra, affecting both men and women [3]. The International Agency for Research on Cancer (IARC) estimated a high incidence of urological cancer cases worldwide; therefore, these diseases have one of the most significant economic and workload on health systems, especially in high and middle-income countries [4].

Urological cancer is a complex disease that can be studied in four stages: prevention, diagnosis, prognosis, and treatment. These four phases are complementary and transversal in the life of a patient. Each phase has limitations or problems that have been discussed over time and require a solution that has a multidisciplinary approach. In prevention, for example, in prostate cancer, different risk factors have been identified, increasing the chance of developing the disease: genetic predisposition [5], an unbalanced diet [6], and excessive consumption of alcohol and tobacco [7]. Being a multifactorial problem, its solution must be multidisciplinary since the individual must be addressed in each one of its facets, using different disciplines [8]. Only a multidisciplinary approach would make it possible to change the modifiable risk factors that reduce the number of cases yearly, such as nursing, psychology, social work, genetics, nutrition, epidemiology, and general medicine.

In the case of diagnosis and prognosis for prostate cancer, there is currently a low rate of early diagnosis. In most cases, this leads to disease identification when it is advanced and, therefore, difficult to establish a timely treatment for preventing complications [7]. This problem demands the formation of a multidisciplinary team that encompasses both basic and clinical sciences and allows the identification of new biomarkers that work for early diagnosis and establishment of risk, allowing the specialist to estimate a patient's prognosis [9]. In such cases, the urology specialist's field of action and knowledge is limited to covering multiple elements, such as bioavailability, formation, and excretion cycles of measurable molecules, and applying techniques that allow their identification and quantification with high sensitivity and specificity [10]. Furthermore, this type of research will reduce the use of invasive standardized tests [11] in routine for diagnosing various urological cancers, reducing the psychological burden of patients with suspected urological cancer.

For treatment, a multidisciplinary team would allow the creation and standardization of new therapies or pharmacological treatments that combine basic and clinical science and help formulate new alternatives for patients with atypical cases or who are resistant to routine treatments [11]. Because these problems require a multidisciplinary intervention for

an efficient solution, the approach and construction of a cancer center of excellence (CCEs) takes strength; this is a specialized and multidisciplinary space that provides comprehensive care, supporting research, and educational instruments for solving problems related to cancer [12].

Therefore, and based on the need to stimulate the formation of multidisciplinary teams that provide comprehensive care to a patient with urological cancer, we aimed to review the multidisciplinary management of patients in uro-oncology, taking as an example of the usefulness of CCEs covering three main areas: educational, care and research.

EPIDEMIOLOGY OF UROLOGIC CANCERS

Urological cancers represent 12.6% of the total cancer cases reported worldwide, with an estimated 2.5 million cases exceeding the number of breast cancer cases (2.2 million) annually [13]. Prostate cancer is the most common urological cancer of all and occupies the fourth position as the most common type of cancer in the world, with an average report of 1.4 million cases and 375,000 deaths, with cases reported mainly in Europe (473,344) and North America (239,574) [14]; followed by bladder cancer, which reports an average of 573,000 cases per year and with a report of 212,536 associated deaths [15], in third place is kidney cancer and renal pelvis carcinoma with 431,288 cases and 179,368 deaths [16], in fourth place is cancer of testis with 74,458 and 9,934 deaths [17], the least frequent of all is the penile cancer with 36,068 cases and 13,211 deaths [18].

The highest fatality rate for 2020 is kidney cancer at 42 %, and penis and bladder cancer with values of 37% each. Prostate cancer has a fatality rate of 27% and testicular cancer of 13%; these fatality percentages must be considered because each type of urological cancer has different percentages of adverse outcomes, and therefore, multidisciplinary interventions must be directed accordingly. The following figure summarizes the percentage of reported cases and deaths discriminated by type of urological cancer, according to the International Agency for Research on Cancer (Figure 1).

Latin America is considered an emerging region due to the increase in the reported number of cases of urological cancers [19]; by the year 2020, almost 302,992 cases and 90,112 deaths were reported, with an overall fatality rate of 27.7% [13]. The magnitude of these cancers places urological cancers as one of the leading causes of consultation, morbidity, and mortality in the world, generating an increase in the cost of health services and a decrease in life expectancy, especially in low- and middle-income countries [4]. This problem must be considered to stimulate the formation of multidisciplinary teams, which cover a complete panorama and allow the generation of valuable proposals to improve the lives of people with urological cancer.

A MULTIDISCIPLINARY TEAM: THE ROLE OF CANCER CENTERS OF EXCELLENCE

The multidisciplinary approach to cancer diagnosis, prognosis, and treatment is not new, but its systematic implementation and functionality are still lacking in many countries [20]. Currently, multidisciplinary has been widely implemented in hospital centers of level 3 and above, with the so-called "tumor committee," which is a multidisciplinary team composed of different medical-surgical specialties and nursing specialties that discuss and evaluate cases of cancer with or without a definitive diagnosis to establish a clear path of care and appropriate intervention. Traditionally, this committee may be composed of two committee representatives (physicians), one representative from each medical-surgical specialty associated with the cancer case to be evaluated, two oncologists, a mental health professional, nursing staff, and two cancer researchers (epidemiologists or basic science), among others [21]. Implementing these committees has brought many benefits to the patient's health since the patient's case is analyzed with a broader view, and more precise and efficient interventions can be made [20]. Despite this, the tumor committees only cover the care area (hospital) and leave out educational and basic research, which are exclusive and, therefore, not genuinely interdisciplinary.

A CCE is defined as a highly specialized and multidisciplinary space that provides quality and humanized care to patients suffering from an oncological process. It should be clarified that the centers of excellence are not exclusive to oncological treatment but can be from other surgical specialties, such as orthopedics, becoming reference centers [22,23]. These centers would not function as regular hospitals but as centers specialized in the diagnosis, treatment, and management of patients with oncological diseases; based on tumor committees, they would be made up of representatives of different surgical specialties [12], oncologists and nursing specialists, unlike the ones that would have more significant interaction with academia to propose both basic and clinical research to improve some of the areas of cancer patients. The CCEs function as specialized units for the comprehensive management of patients with urological cancers and would build bridges allowing their integration with academia and research. The following figure represents the CCEs' interactions for managing uro-oncology patients (Figure 2).

As can be seen, the CCEs are the central part of this multidisciplinary team and are related to its three main areas: education, research, and healthcare. This approach is much more complete because it not only stimulates comprehensive care for patients but also allows them to analyze the situation and take them as a reference to stimulate research that allows them to understand the illness better and propose alternatives that improve the situation. All this, under the strict rules of ethical approval of research and work with humans[24], respecting the integrity, will, and life of the people whom the CCEs treat. The implementation of CCEs is not new for the comprehensive management of patients with urological cancers; the European Urology Society (EUS) has proposed its creation and

implementation for the comprehensive management of patients with prostate cancer because it is the primary urological cancer in the world and has even launched a list of minimum functionality and quality requirements for its operation. For a CCEs to function, it must be composed of three elements or areas: A clinical or healthcare area, an education or educational area, and a research area, each with a series of requirements and minimum quality standards that allow its authorization and accreditation [22]. We will explain the previous in detail in the following lines:

THE HEALTHCARE AREA

The main characteristic of a CCEs is that it must have a multidisciplinary team that allows the disease to be covered from a physiological, psychological, and social point of view [25]. EUS proposes the following professionals as human talent: it must be made up of a minimum number of different specialist physicians, including a urologist, radiation oncologist, medical oncologist, pathologist, and radiologist; associated services such as nursing, psychology and mental health, physiotherapy, sex therapists, physical therapists, and palliative care specialists; diagnostic routes that include standard tests for diagnosis, monitoring and prognosis and finally a clear treatment route offering varieties, alternatives and that are certified by national or international regulatory bodies [22]. In addition, the facilities that the healthcare area must have must comply with all the minimum necessary regulations according to the country where it is located, have a space that allows patients to gather, listen to them, and actively participate in all the activities carried out by the hospital center, the patient's comfort must be prioritized in the architecture of the space, also stimulating spaces for recreation and leisure [23]. There must also be spaces for academic discussion that allow interaction between different professionals to formulate ideas, projects, and strategies for comprehensive care for patients with oncological diseases [23].

Among the countries that have approved the formation of CCEs is the United States. Since 2017, the construction of these centers has been regulated, which has increased the focus of resources and efforts for testing new oncological therapies, allowing a cost reduction and increasing the number of clinical trials since it is easier to identify individuals [26]. The interdisciplinarity conversation between different professionals that characterizes a CCEs has had positive effects in social contexts, increasing and focusing efforts to identify cases of cancer in ethnic groups and/or minorities that, due to structural conditions of society, have been underdiagnosed or not treated in routine hospitals. Thanks to CCEs, the participation of African Americans in cancer studies in the U.S. has increased, raising their participation levels from 5% to 13.3%, guaranteeing more excellent representation of the disease in the population and considering specific variables that are decisive in the treatment [27]. It has also contributed to reducing economic inequalities in accessing cancer treatment, especially in low-income countries such as Rwanda and disadvantaged populations such as children, focusing resources more efficiently and reducing the final cost to the patient, increasing accessibility to a larger population [28].

Despite all the benefits CCEs have brought, several limitations have also been identified. For example, in emergencies such as the SAR-COV2 pandemic in 2020, many of the CCEs in Germany were not prepared to face a new form of care, generating a decrease of 21 % in the provision of care and treatment to different oncological processes [29], it also generated flare-ups and recrudescence of the disease in patients, leading to severe consequences. However, the pandemic generated problems worldwide and altered how patients were cared for. It is essential to mention it since these CCEs must reformulate the strategies for monitoring and providing care if a similar situation is repeated. Another of the main limitations that a CCEs may have is that, like a routine clinic or hospital, it only offers treatment for widespread situations, ignoring treatment for people with rare diseases or uncommon variations in developing countries. Developing a few centers of excellence would further limit care coverage and the marginalization of cases [30]. The following table summarizes the main characteristics that a CCEs must meet, focusing on the comprehensive management of patients with urological cancers, following what is established by the EUS (Table 1).

THE EDUCATIONAL AREA

The EUS proposes that CCEs focused on the comprehensive management of urological cancers should help train young doctors and researchers, stimulating their research interests. A minimum of one year of training should be proposed, which can be divided in the case of doctors into one year only clinically or into two phases: the first six months of comprehensive and clinical management of patients with urological cancers and six months of basic research. One year of basic research must be stipulated for the rest of the interdisciplinary group, not a doctor or health professional caring for patients. If a urologist is being trained at the CCEs, the EUS establishes that they must receive training in basic urology, oncological medicine, and oncological radiology [22]. To do this, principal researchers must have active research projects once the students enter and function as mentors or guides for doctors or researchers in training. These projects may have a clinical or primary focus and must be linked to some activity. This is what CCEs do in the comprehensive management of patients with urological cancers.

The CCEs become training institutions for professionals in various fields, allowing training at almost all levels of university education from undergraduate to clinical graduate degrees, such as specialties in urology, urologic oncology, oncology, or radiation oncology, including MSc and Ph.D. degrees. This training can be focused on different areas, such as palliative care, mental health promotion, and basic and/or clinical investigation [31]. The CCEs offer comprehensive training to urologists and oncologists through internships. For example, in the USA, different institutes offer training in managing urological cancers through developing surgical skills, treatment alternatives, and the study and management of rare variations of urological diseases or sporadic cancers [32]. For example, among urological cancers, the rarest of all are penile and urethral cancer; it is estimated that only

17% of urologists manage to treat at least one case in their first five years of professional practice. Therefore, CCEs specialized in the comprehensive management of penile cancer have become an excellent option to train urologists capable of treating any patient with uro-oncological problems [31,33]. It also stimulates residents and professionals to enter the area of research by linking their academic training with problems that require a solution. Nursing is the cornerstone in intensive care, palliative and mental health promotion in patients, companions, and family members; the linking of undergraduate and graduate students in nursing has given good results [34], as it stimulates their education skills in primary and secondary prevention of diseases, also stimulates the formation of specialists in areas of oncological care among others. Regarding the training for MSc and PhD, the alliance with universities can be critical in the initial stages. However, it is possible to train these types of graduate courses in the same center. For example, research centers in the United Kingdom offer their master's programs in oncology with both clinical and basic science approaches [35], having advantages in locating patients with particular characteristics with which projects can be developed. Little is known about the advantages and learning that undergraduate students would have. However, institutions such as Florida Atlantic University invite their undergraduate students in health sciences to participate in the center's activities to learn about the management of certain types of patients with complicated diseases, stimulating their interest in research in basic or clinical sciences [36]. Because CCEs are centers for comprehensive patient care and management, all their care protocols must be based on updated clinical guidelines for urological care and endorsed by urology/oncology societies recognized by state organizations. These guidelines must be discussed with the personnel and ratified by experts that guarantee compliance with the highest quality standards [22,37]. One of the main limitations that CCEs would face in their educational field would be the lack of communication between the various actors involved in education, especially if the entry of university institutions into multidisciplinary work is proposed. However, communications between educational health professionals and universities have improved, and there is still much to work on [38].

THE RESEARCH AREA

Although education and research go hand in hand, they are different. On the contrary, they are complementary, further explaining interdisciplinarity's importance. The EUS also establishes a series of considerations that must be considered for the opening and functioning of the research area, among them the collection of information on treated individuals, discriminated by type of cancer, evolution, treatment, follow-up, interventions, and outcomes, to provide important information that allows decisions to be made based on collected evidence [22]. As in the educational area, the universities have an essential role in countries like Colombia since they are the leading research centers and those that produce most of the country's knowledge. In addition, they have also overseen appropriating social knowledge and its dissemination to different communities [39].

Research in CCEs can have three main focuses: basic, translational, and clinical investigation [22]. On the one hand, we have basic research focuses mainly on the search for valuable elements that allow support for the diagnosis and treatment of different urological cancers, either through the identification of new biomarkers that help identify early cases of different types of urological cancers, improving the prognosis of patients and reducing the possibilities of complications associated with the oncological process, several studies have been developed to support the diagnosis of different urological cancers, such as the implementation of CRISP as a screening test for the detection of prostate cancer [40], the use of microRNAs as potential markers for prognosis and diagnosis of the prostate [41,42] and bladder cancer[43], all these elements include tools provided from the basic sciences. Therefore, forming multidisciplinary teams that allow the entry of biologists and basic science researchers is essential.

On the other hand, we have clinical research, which allows the application and evaluation of different elements related to the oncological process, mainly treatments, evaluating their efficiency and effectiveness; this branch of research, although it is also multidisciplinary, must be headed by medical specialists and can serve as a complement to the basic one by functioning as an applicator of its proposals. The CCEs become specialized centers for applying randomized clinical trials since they allow for identifying, characterizing, managing, and monitoring patients with oncological diseases. This would help us better understand their disease and propose solutions that improve their quality of life[30]. These projects can focus on different types of urological cancer. They could allow the evaluation of the safety of certain medications or compounds that would serve as pharmacological [44]therapies, all under strict supervision and approval of an ethics committee.

Globalization and the connection of people have led to research becoming globalized and the exchange of ideas and resources between researchers. Thanks to this, the exchange of research in public health has been allowed, allowing us to improve the conditions of life of patients with urological cancers in countries that do not have the resources to implement such complex clinical trials [45]. Translational research has had positive effects, especially in countries with little human capital, since it allows the mobilization of researchers for collective learning and to build support networks that improve the living conditions of patients suffering from similar situations and, therefore, stimulate interdisciplinary research [46].

Publications are a mandatory criterion to guarantee quality in the educational and research area in a CCEs; it is mandatory to produce at least one publication per student during their period [22]. To achieve this objective, there must be monitoring by the mentors and a commitment by the students to begin proposing ideas, writing articles and projects, and publishing them. Universities are the main, or only in some cases, centers of research, both clinical and basic, especially in low- and middle-income countries, which do not have

significant industrial progress [47]. Therefore, the alliance between CCEs and universities in Colombia seems to be among the best options to stimulate and promote comprehensive research [12]. For example, the alliance between public universities and university hospitals has allowed the comprehensive training of multiple professionals in the health area and stimulates both clinical and basic research for the understanding of different diseases; they play and would play a fundamental role in the consolidation of CCEs [48], strengthening their competencies in basic and clinical research, providing experience, facilities, equipment, and personnel.

CONCLUSIONS

Urological cancers are complex to diagnose, manage, and treat; therefore, they require comprehensive multidisciplinary management that guarantees care with the highest possible quality standards. In addition, the CCEs become a tempting alternative that allows not only the multidisciplinary of medical-surgical specialties but also stimulates the entry of academics and research into the discussion, allowing to solve problems seen while treating patients with urological cancers.

REFERENCES

1. Yin W, Wang J, Jiang L, James Kang Y. Cancer and stem cells. *Exp Biol Med (Maywood)* 2021;246:1791-801. <https://doi.org/10.1177/15353702211005390>
2. Li D, Li Y, Bai X, Wang M, Yet al. The effects of aromatherapy on anxiety and depression in people with cancer: A systematic review and meta-analysis. *Front Public Health* 2022;10:853056. <https://doi.org/10.3389/fpubh.2022.853056>
3. Bergengren O, Pekala KR, Matsoukas K, et al. 2022 update on prostate cancer epidemiology and risk factors-A systematic review. *Eur Urol* 2023;84:191-206. <https://doi.org/10.1016/j.eururo.2023.04.021>
4. Porcaccia AS, Pires GN, Ortiz V, Andersen ML, Tufik S. Prostate cancer mortality and costs of prostate surgical procedures in the Brazilian public health system. *Int Braz J Urol* 2022;48:583–90. <https://doi.org/10.1590/s1677-5538.ibju.2021.0781>
5. Seibert TM, Garraway IP, Plym A, et al. Genetic risk prediction for prostate cancer: Implications for early detection and prevention. *Eur Urol* 2023;83:241-8. <https://doi.org/10.1016/j.eururo.2022.12.021>
6. Matsushita M, Fujita K, Nonomura N. Influence of diet and nutrition on prostate cancer. *Int J Mol Sci* 2020;21:1447. <https://doi.org/10.3390/ijms21041447>
7. Berenguer CV, Pereira F, Câmara JS, et al. Underlying features of prostate cancer-statistics, risk factors, and emerging methods for its diagnosis. *Curr Oncol* 2023;30:2300-21. <https://doi.org/10.3390/curroncol30020178>
8. Wirth M, Fossati N, Albers P, et al. The European prostate cancer centres of excellence: A novel proposal from the European Association of Urology Prostate Cancer Centre consensus meeting. *Eur Urol* 2019;76:179–86. <https://doi.org/10.1016/j.eururo.2019.01.033>
9. Matuszczak M, Schalken JA, Salagierski M. Prostate cancer liquid biopsy biomarkers' clinical utility in diagnosis and prognosis. *Cancers (Basel)* 2021;513:3373. <https://doi.org/10.3390/cancers13133373>
10. CN Molokwu, T Naqvi, D Tyson. Multidisciplinary team management of patients with urological cancer. *Br J Hosp Med* 2019;80:699–702. <https://doi.org/10.12968/hmed.2019.80.12.699>
11. Xu Y, Luo C, Wang J, et al. Application of nanotechnology in the diagnosis and treatment of bladder cancer. *J Nanobiotechnology* 2021;19:393. <https://doi.org/10.1186/s12951-021-01104-y>
12. García-Perdomo HA. Cancer centers of excellence in Colombia: A fundamental way to work together. *Urol Colomb* 2017;26:157-8. <https://doi.org/10.1016/j.uroco.2017.08.002>
13. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today [Internet]. 2020. Available from: <https://gco.iarc.fr/today>
14. Ferlay j, Ervik m, lam f, Colombet m, Mery l, Piñeros. Prostate Source: Globocan 2020 Number of new cases in 2020 [Internet]. 2020. Available from: <https://gco.iarc.fr/today>
15. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M. Global Cancer Observatory: Bladder and urological cancer. 2020.
16. Ferlay j, Ervik m, lam f, Colombet m, Mery l, Piñeros. Kidney: Number of Cases 2020 [Internet]. 2020. Available from: <https://gco.iarc.fr/today>

17. Ferlay j, Ervik m, lam f, Colombet m, Mery l, Piñeros. Testis: Number of cases 2020 [Internet]. 2020. Available from: <https://gco.iarc.fr/today>
18. Ferlay j, Ervik m, lam f, Colombet m, Mery l, Piñeros. Penis: Number of Cases 2020 [Internet]. 2020. Available from: <https://gco.iarc.fr/today>
19. Reis RBD, Alías-Melgar A, Martínez-Cornelio A, et al. Prostate cancer in Latin America: Challenges and recommendations. *Cancer Control* 2020;27:1073274820915720. <https://doi.org/10.1177/1073274820915720>
20. Blackwood O, Deb R. Multidisciplinary team approach in breast cancer care: Benefits and challenges. *Indian J Pathol Microbiol* 2020 Feb;63:S105-12. https://doi.org/10.4103/IJPM.IJPM_885_19
21. Rankin NM, Lai M, Miller D, et al. Cancer multidisciplinary team meetings in practice: Results from a multi-institutional quantitative survey and implications for policy change. *Asia Pac J Clin Oncol* 2018;14:74–83. <https://doi.org/10.1111/ajco.12765>
22. Wirth M, Fossati N, Albers P, et al. The European prostate cancer centres of excellence: A novel proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. *Eur Urol* 2019;76:179–86. <https://doi.org/10.1016/j.eururo.2019.01.033>
23. Elrod JK, Fortenberry JL Jr. Centers of excellence in healthcare institutions: What they are and how to assemble them. *BMC Health Serv Res* 2017;17:425. <https://doi.org/10.1186/s12913-017-2340-y>
24. Martínez IP, Alvarez RM. Importance of research ethics committees in family medicine. *Aten Primaria* 2019;51:263-5. <https://doi.org/10.1016/j.aprim.2019.04.001>
25. Wolfson JA, Sun CL, Wyatt LP, et al. Impact of care at comprehensive cancer centers on outcome: Results from a population-based study. *Cancer* 2015;121:3885-93. <https://doi.org/10.1002/cncr.29576>
26. Goldberg KB, Blumenthal GM, McKee AE, et al. The FDA Oncology Center of Excellence and precision medicine. *Exp Biol Med* 2018;243:308–12. <https://doi.org/10.1177/1535370217740861>
27. Regnante JM, Richie NA, Fashoyin-Aje L, et al. US cancer centers of excellence strategies for increased inclusion of racial and ethnic minorities in clinical trials. *J Oncol Pract* 2019;15:e289-9. <https://doi.org/10.1200/jop.18.00638>
28. Claire Neal, Christian Rusangwa, Ryan Borg, et al. Cost of treating pediatric cancer at the Butaro Cancer Center of Excellence in Rwanda. *J Glob Oncol* 2018;4:1–4. <https://doi.org/10.1200/JGO.17.00155>
29. Arndt V, Doege D, Fröhling S, et al. Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic. *J Cancer Res Clin Oncol* 2023;149:913-9. <https://doi.org/10.1007/s00432-022-04407-1>
30. Sandrucci S, Naredi P, Bonvalot S. Centers of excellence or excellence networks: The surgical challenge and quality issues in rare cancers. *Eur J Surg Oncology* 2019;45:19–21. <https://doi.org/10.1016/j.ejso.2017.12.012>
31. Qoronfleh MW. Pathway to excellence in cancer care: Learning from Qatar's experience. *Precision Medical Sciences* 2020;9:51–61. <https://doi.org/10.1002/prm2.12027>

32. Saint John's Cancer Institute. Urology. 2018. p. 1–10.
33. Kamel MH. Should the care of penile cancer be confined to centralized centers of excellence? *Eur Urol Focus* 2019;5:735-6.
<https://doi.org/10.1016/j.euf.2019.01.013>
34. Rugen KW, Watts SA, Janson SL, et al. Veteran Affairs centers of excellence in primary care education: Transforming nurse practitioner education. *Nurs Outlook* 2014;62:78–88. <https://doi.org/10.1016/j.outlook.2013.11.004>
35. Cancer and Clinical Oncology MSc.
36. Cancer center of excellent.
37. Velasco-Zamora JA, Gómez-Reyes E, Uscanga L. Are the clinical guideline recommendations on gastroprotection being followed? A review in patients taking nonsteroidal anti-inflammatory drugs. *Rev Gastroenterol Mex* 2016;81:121–5.
<https://doi.org/10.1016/j.rgmx.2016.04.001>
38. Juárez-Carrillo PM, Liebman AK, Reyes IAC, et al. Aplicación de la teoría de aprendizaje en el entrenamiento acerca de seguridad y salud para trabajadores inmigrantes en las lecherías. *Health Promot Pract* 2018;3:1524839918812419.
<https://doi.org/10.4321/S0465-546X2019000300001>
39. Gaviria-Velásquez MM, Mejía-Correa AM. Apropiación social de la ciencia y comunicación pública del conocimiento, dos actividades inherentes a la investigación universitaria. *Revista Interamericana de Bibliotecología* 2021;44:e2659. <https://doi.org/10.17533/udea.rib.v44n3e343603>
40. Tsujino T, Komura K, Inamoto T, et al. CRISPR screen contributes to novel target discovery in prostate cancer. *Int J Mol Sci* 2021;22:12777.
<https://doi.org/10.3390/ijms222312777>
41. Fabris L, Ceder Y, Chinnaiyan AM, et al. The potential of microRNAs as prostate cancer biomarkers. *Eur Urol* 2016;70:312-22.
<https://doi.org/10.1016/j.eururo.2015.12.054>
42. Zhu KC, Lu JJ, Xu XL, et al. MicroRNAs in androgen-dependent PCa. *Front Biosci (Landmark Ed)* 2013;18:748-55. <https://doi.org/10.2741/4137>
43. Taheri M, Shirvani-Farsani Z, Ghafouri-Fard S, et al. Expression profile of microRNAs in bladder cancer and their application as biomarkers. *Biomed Pharmacother* 2020;131:110703. <https://doi.org/10.1016/j.biopha.2020.110703>
44. Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. *Cancer* 2022;128:2085–97. <https://doi.org/10.1002/cncr.34180>
45. Domingo-Maglinao MaL, Mercado-Asis LB. Promoting academic exchange in public health: A transnational education model. *Journal of Medicine, University of Santo Tomas* 2021;5:699–705. <https://doi.org/10.35460/2546-1621.2020-0060>
46. da Silva RGL, Blasimme A. Organ chip research in Europe: players, initiatives, and policies. *Front Bioeng Biotechnol* 2023;11:1237561.
<https://doi.org/10.3389/fbioe.2023.1237561>
47. Lovakov A, Chankseliani M, Panova A. Universities vs. research institutes? Overcoming the Soviet legacy of higher education and research. *Scientometrics* 2022;127:6293–313. <https://doi.org/10.1007/s11192-022-04527-y>

48. Ortiz Martínez JG. Hospitales universitarios en Colombia: desde Flexner hasta los centros académicos de salud. *Repertorio de Medicina y Cirugía* 2016;25:50–8. <https://doi.org/10.1016/j.reper.2016.02.001>

DRAFT

FIGURES AND TABLES

Figure 1. Epidemiology of urological cancers in the world 2020. (A) Percentage of reported cases, in both sexes, of primary urologic cancers. (B) Percentage of associated deaths by type of urological cancers in both sexes.




Figure 2. Mind map of the working relationship between the uro-oncology units of the cancer centers of excellence and the healthcare, educational, and research areas.




Table 1. Minimum characteristics are necessary for constructing a CCEs for urologic cancer according to the EAU			
Main features by area in a CCEs for uro-oncology	Healthcare area	Educational area	Research area
	Medical specialties: urologist, radiation oncologist, medical oncologist, pathologist, and radiologist	Programs for training specialists such as urologists and oncologists	Projects that allow the publication of at least 1 scientific article per year
	Associated services: nursing, psychology and mental health, physiotherapy, sex therapists, physical therapists, and palliative care specialists	MSc and PhD programs, either at the center or in alliance with local universities	Ethics committee that guarantees the integrity of the participants and allows their active participation in research projects
	Diagnostic routes: standard tests for diagnosis, monitoring and prognosis and finally	Undergraduate student bonding	There must be projects led by a principal investigator who follows up and encourages the involvement of others.
	Clear treatment route: varieties, alternatives and that are certified by national or international regulatory bodies	Research projects that link students in training	Support integration and multidisciplinary work

CCE: cancer center of excellence; EAU: European Association of Urology.